Anticancer activity of cardiac glycosides
Open Access
- 1 December 2012
- journal article
- Published by Taylor & Francis Ltd in OncoImmunology
- Vol. 1 (9), 1640-1642
- https://doi.org/10.4161/onci.21684
Abstract
Retrospective clinical data indicate that cardiac glycosides (CGs), notably digoxin, prolong the survival of carcinoma patients treated with conventional chemotherapy. CGs are known to influence the immune response at multiple levels. In addition, recent results suggest that CGs trigger the immunogenic demise of cancer cells, an effect that most likely contributes to their clinical anticancer activity.Keywords
This publication has 12 references indexed in Scilit:
- Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell DeathScience Translational Medicine, 2012
- Trial watchOncoImmunology, 2012
- The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 2012
- Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemiaOncogene, 2011
- A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer TreatmentCancer Discovery, 2011
- Digoxin Use and the Risk of Breast Cancer in WomenJournal of Clinical Oncology, 2011
- Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activityNature, 2011
- Cardiac glycosides are potent inhibitors of interferon-β gene expressionNature Chemical Biology, 2010
- Decoding Cell Death Signals in Inflammation and ImmunityCell, 2010
- Cardiac Glycosides Induce Cell Death in Human Cells by Inhibiting General Protein SynthesisPLOS ONE, 2009